Modalis Therapeutics Corporation

4883

TSE PrimePharmaceuticals

¥ -

You can review earnings summary, quarterly trends, full-year progress, and detailed income statement data.

descriptionIncome Statement (PL) Summary

Updated: 2026-08-14FY2026 Q2

Revenue

YoY -

Operating Income

-9.9100M JPY

YoY +4.1%

Net Income

-20.4100M JPY

YoY -31.1%

EPS

-9.8JPY

YoY +28.5%

Performance Trend

Revenue, operating income and net income trend (last 5 periods)

RevenueOperatingNet Income

40百万円

-6.5億円

-13.3億円

-20.2億円

-27億円

Rev: 1百万円Op: -12.4億円NI: -7.4億円

Rev: 40百万円Op: -20.6億円NI: -27億円

Rev: -Op: -23.7億円NI: -23.9億円

Rev: -Op: -13.4億円NI: -13.2億円

Rev: -Op: -22.1億円NI: -21.5億円

2021/FY2022/FY2023/FY2024/FY2025/FY

Full-Year Progress

FY2026 Q2

Net Income-

Revenue Progress-

Revenue Forecast-

Net Income Progress-9.100M

Net Income Forecast-

Income Statement Details

Unit: JPY

Unlock Long-Term Financial Data

Your current plan allows viewing financial data for the latest 1 year (annual only). Upgrade to the Standard Plan to view up to 3 years (including quarterly data), or the Premium Plan to access all historical data.

Standard Plan Premium Plan